The Future of the Aging Eye
AnnMarie Hipsley, the Founder and CEO of Ace Vision Group (AVG), a Delaware, USA- based company developing innovative therapeutics for age-related ocular dysfunctions, talks to The Ophthalmologist about her background and work with AVG, and the company’s short- and long-term goals.
She explains how the Group has utilized artificial intelligence and virtual reality platforms to develop the Next Gen VisioLite laser, paints a broad picture of the current gaps in available treatment models for age-related eye diseases, such as presbyopia, and goes into detail about how Laser Scleral Microporation Therapeutic Laser Rejuvenation (LSM) eye therapy sits within the future landscape of treatments for these disorders.
Explore More Articles
The Answer for Aging Eyes?
The accommodation mechanism is the core moving “engine” of the eye – responsible for dynamic range of visual focus, as well as hydrodynamic equilibrium and circulatory functions. Doesn’t it seem likely that there would be potential ocular health benefits in rejuvenating rigid ocular tissues? Today, there still is no authentic viable therapeutic to rejuvenate ocular …
read moreAce Vision Group Names Rob Kissling, MD, as Chief Medical Officer
Ace Vision Group announced that it has named Rob Kissling, MD, as Chief Medical Officer. Dr. Kissling has more than 20 years of experience integrating clinical development, medical strategy, and business planning to develop and commercialize devices and medicines for ophthalmology. His tenure has included companies such as Pharmacia, Pfizer, and Novartis. Most recently, he …
read moreJackson discusses laser scleral microporation for presbyopia
LAS VEGAS — In this Healio Video Perspective from the ASCRS meeting, Mitchell A. Jackson, MD, discusses preliminary results from a trial investigating laser scleral microporation to treat presbyopia.
read more